Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04012359
Other study ID # 2019/006/OB
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 26, 2019
Est. completion date June 26, 2021

Study information

Verified date November 2022
Source University Hospital, Rouen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Chronic Obstructive Pulmonary Disease (COPD) is a frequent disease affecting a growing number of adults in the world which is responsible for a large public health burden through heavy morbidity and mortality. Emphysema is one of a wide spectrum of pulmonary complications linked to COPD, defined as the abnormal permanent enlargement of the airspaces distal to the terminal bronchioles accompanied by destruction of the alveolar wall. Disease progression is correlated to worsening and enlargement of emphysema lesions, sometimes conflating in sizeable bullae, deleterious to normal mechanical pulmonary function. Bullous emphysema (BE) is sometimes eligible to invasive curative treatment through surgery or interventional bronchoscopy. Diagnosis of BE relies on computerized tomodensitometry (CT), the gold-standard for evaluating pulmonary parenchyma. However, CT is not always available, and bullous emphysema can present as pneumothorax on chest radiography. The practice of lung ultrasound is currently growing in respiratory medicine and emergency departments owing to an increasing amount of evidence showcasing its reliability as a diagnostic tool, most notably for pneumothorax and other pleural diseases. Despite BE having been reported to present similarly to pneumothorax in ultrasound, its characteristics have not yet been precisely described. The primary aim of this study is to describe BE using lung ultrasound. Participants with known BE on CT will undergo a simple ultrasound examination. The secondary aim is to compare the characteristics of BE to those of pneumothorax using lung ultrasound. To achieve this, a second group of participants with currently treated pneumothorax will also undergo lung ultrasound.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date June 26, 2021
Est. primary completion date June 26, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Bullous emphysema group - Consultation or scheduled hospitalization in a Pulmonary Medicine department - Past medical history of emphysema on computerized tomodensitometry dating less than two years - Bullous emphysema with subpleural contact of two or more intercostal spaces on tomodensitometry - Pneumothorax group - Hospitalized in a Pulmonary Medicine department for the treatment of a pneumothorax - Patent pneumothorax visible on chest x-ray dating less than 24 hours Exclusion Criteria: - Bullous emphysema group - Current pneumothorax - Past medical history of pleurodesis or pleural thickening homolateral to the bullous emphysema - All patients - Organ failure (hemodynamic, neurological, respiratory) - Recent thoracic surgery dating less than 7 days with subcutaneous emphysema - Minor participant or otherwise deprived of their freedom or their ability to consent freely - No affiliation to social security

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Lung ultrasound
Non-invasive external ultrasonography of the chest wall
Chest radiography
Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
Pulmonary function tests
Pulmonary function evaluation as part of routine care for emphysematous patients
Other:
Clinical examination
Standard clinical examination performed by investigating physician

Locations

Country Name City State
France Pulmonary Medicine, Thoracic Oncology and Respiratory Intensive Care Department, Rouen University Hospital Rouen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of various ultrasound signs in the bullous emphysema group, according to a predetermined sonographic evaluation form, following a standardized segmentation of the chest The following sonographic signs will be investigated :
Pleural sliding (presence/absence)
Z lines (presence/absence)
A line visibility increase (presence/absence)
B line (number per field)
pulmonary pulse (presence/absence)
lung-point (presence/absence)
intercostoaeric line thickness (in mm)
For qualitative signs, the investigators will present proportions Quantitative signs will be reported using means, medians and standard-deviations
2 years
Secondary Prevalence of various ultrasound signs in the pneumothorax group, according to a predetermined sonographic evaluation form, following a standardized segmentation of the chest The following sonographic signs will be investigated :
Pleural sliding (presence/absence)
Z lines (presence/absence)
A line visibility increase (presence/absence)
B line (number per field)
pulmonary pulse (presence/absence)
lung-point (presence/absence)
intercostoaeric line thickness (in mm)
For qualitative signs, the investigators will present proportions Quantitative signs will be reported using means, medians and standard-deviations
2 years
Secondary Statistical comparison of ultrasound characteristics of bullous emphysema and pneumothorax Calculation of sensitivity values of lung ultrasound for bullous emphysema for each sonographic sign. Study design prohibits calculation of specificity.
A quantitative discrete score will be constructed by enumerating signs which are positive in favor of bullous emphysema, able to discriminate between both diseases. AUC will be calculated. An AUC < 0.75 will be considered as insufficient for establishing lung ultrasound as a diagnostic test for bullous emphysema. An AUC > 0.75 would prompt further studies.
2 years
See also
  Status Clinical Trial Phase
Recruiting NCT00995852 - Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study Phase 2/Phase 3
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00123422 - Innovation in Pulmonary Rehabilitation N/A
Recruiting NCT02879331 - Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils N/A
Completed NCT01507415 - Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD? N/A
Completed NCT01051258 - AeriSeal System for Lung Volume Reduction Phase 1/Phase 2
Completed NCT00680056 - Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients Phase 4
Completed NCT01872624 - Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema N/A
Completed NCT01110252 - Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease N/A
Completed NCT00517998 - Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study Phase 1
Terminated NCT00205920 - Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation Phase 2
Withdrawn NCT01849159 - Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema Phase 1/Phase 2
Completed NCT01869205 - The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients Phase 3
Terminated NCT01320566 - A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema Phase 2/Phase 3
Completed NCT00683722 - PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Active, not recruiting NCT04465461 - Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion N/A
Recruiting NCT04918706 - Allogeneic MSC Treatment for Pulmonary Emphysema Phase 2
Terminated NCT01449292 - Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) Phase 3
Completed NCT00347659 - US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study Phase 1
Recruiting NCT02827721 - Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)